BioSpace News Archive

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, announced the U.S. Food and Drug Administration has accepted and filed the Company’s efficacy supplement to the Biologics License Application for ELEVIDYS .

Y-mAbs Therapeutics, Inc. announced that it will report its financial results for the quarter and full year ended December 31, 2023, on Thursday, February 29, 2024, after the close of the U.S. financial markets.

Autonomix Medical, Inc. announced the completion of its site initiation for its proof-of-concept human clinical study evaluating the use of transvascular RF ablation for the treatment of pancreatic cancer pain.

Chromocell Therapeutics Corporation announced the pricing of its initial public offering of 1,100,000 shares of common stock at a public offering price of $6.00 per share.

Arcutis Biotherapeutics, Inc. announced that it will report its fourth quarter and full year financial results and provide a business update on Tuesday, February 27, 2024.

Hepion Pharmaceuticals, Inc. announced that it has entered into a definitive agreement for the immediate exercise of an outstanding Series B common stock purchase warrant held by an institutional investor to purchase an aggregate of 980,393 shares of Hepion common stock for gross proceeds to the Company of approximately $2.0 million.

Kinnate Biopharma Inc. announced it has entered into a definitive merger agreement whereby XOMA Corporation will acquire Kinnate for a price per share of Kinnate common stock of between $2.3352 and $2.5879 in cash, consisting of a base cash price of $2.3352 per share and an additional cash amount of up to $0.2527 per share.

XOMA Corporation announced it has entered an agreement to acquire Kinnate Biopharma Inc. for a base cash price of $2.3352 per share and an additional cash amount of not more than $0.2527 per share at the closing of the merger plus a non-transferable contingent value right.

Viridian Therapeutics, Inc., a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, announced the appointment of Jennifer Tousignant to the role of Chief Legal Officer.

For the 11th consecutive year, Thermo Fisher Scientific’s pharma and biopharma customers recognized its contract manufacturing excellence through the annual CDMO Leadership awards sponsored by Outsourced Pharma and Life Science Connect.